Diffuse large B-cell lymphoma refractory – Diagnostics – Overview of Information and Clinical Research

Diffuse large B-cell lymphoma refractory is a challenging condition where the disease either doesn’t respond to initial treatment or comes back after seeming to go away. Understanding how doctors identify and confirm this type of lymphoma is essential for patients and families navigating this difficult journey.

Introduction: Who Should Undergo Diagnostics

Diagnosing refractory diffuse large B-cell lymphoma typically becomes necessary when a patient’s disease doesn’t respond as expected to treatment. If you’ve already been treated for diffuse large B-cell lymphoma with standard chemotherapy, your doctor will want to check whether the disease is truly gone or if it has returned. The term relapsed means the disease has come back after a period when it seemed to have disappeared, called remission. The term refractory describes a situation where the lymphoma never really responded to treatment in the first place, meaning the cancer cells kept growing despite therapy, or any improvement didn’t last very long.^[1]

People who should seek diagnostic evaluation include those who notice new symptoms after completing treatment, such as swollen lymph nodes that weren’t there before, unexplained fever, night sweats, or unusual tiredness. Patients who never achieved complete remission during their first treatment course also need careful diagnostic assessment to understand whether their disease is truly refractory. Additionally, anyone whose imaging scans during or after treatment show concerning findings should undergo further diagnostic procedures to confirm what’s happening inside their body.^[3]

It’s particularly important to seek diagnostic testing if you experience symptoms within the first year after completing initial treatment. Research has shown that patients whose disease returns within twelve months of finishing chemotherapy, or those whose disease never responded adequately to six cycles of chemotherapy, represent the highest-risk group and require prompt evaluation and different treatment approaches than those whose disease returns later.^[4]

⚠️ Important

Before starting any new treatment for suspected relapsed or refractory disease, doctors strongly recommend repeating a tissue biopsy. This is crucial because imaging tests can sometimes give false-positive results, showing what looks like cancer when it might be something else entirely, such as inflammation, infection, or even completely different diseases like tuberculosis or fungal infection. A fresh biopsy ensures you receive the right treatment for the actual condition affecting your body.^[6]

Diagnostic Methods for Relapsed or Refractory Disease

Physical Examination

The diagnostic process for relapsed or refractory diffuse large B-cell lymphoma typically begins with a thorough physical examination. Your doctor will carefully check for swollen lymph nodes in specific areas of your body, including your neck, underarms, and groin. These are common places where lymphoma can cause lymph nodes to enlarge. The doctor will also examine your abdomen to determine if your spleen or liver feels larger than normal, which can indicate that lymphoma has spread to these organs.^[3]

During this examination, your healthcare provider is looking for physical signs that might indicate the disease has returned or never fully went away. While a physical exam alone cannot confirm relapsed or refractory disease, it provides important initial clues that guide which additional tests should be ordered.

Blood Tests

Blood tests play an important role in evaluating suspected relapsed or refractory disease, even though they cannot definitively diagnose lymphoma on their own. Sometimes blood tests can reveal the presence of lymphoma cells circulating in the bloodstream. More commonly, they help doctors understand your overall health status and look for specific markers that often appear in people with active lymphoma.^[3]

One particularly important blood test measures the level of lactate dehydrogenase, often abbreviated as LDH. This enzyme is frequently elevated in people with active lymphoma. When LDH levels are high, it can suggest that lymphoma is present and actively growing in the body. Blood tests also check for certain viruses that can affect lymphoma behavior, including Epstein-Barr virus, HIV, hepatitis B, and hepatitis C.^[3]

Imaging Tests

Imaging tests create detailed pictures of the inside of your body and are essential for determining where lymphoma might be located and how extensive it is. These tests help doctors visualize areas that cannot be seen or felt during a physical examination. Several different types of imaging tests may be used when evaluating relapsed or refractory diffuse large B-cell lymphoma.^[3]

Magnetic resonance imaging, or MRI, uses powerful magnets and radio waves to create detailed images of soft tissues in your body. Computed tomography, commonly called a CT scan, uses X-rays taken from multiple angles and combines them with computer processing to create cross-sectional images of bones, blood vessels, and soft tissues. Positron emission tomography, known as a PET scan, involves injecting a small amount of radioactive sugar into your body; cancer cells, which use more energy than normal cells, absorb more of this sugar and show up as bright spots on the scan.^[3]

These imaging tests are crucial not just for finding disease but also for determining whether the lymphoma is confined to lymph nodes or has spread to other organs. This information significantly impacts treatment decisions and helps doctors understand the full extent of the disease.

Tissue Biopsy

A biopsy involves removing a sample of tissue so it can be examined under a microscope in a laboratory. This is the most definitive way to confirm whether relapsed or refractory diffuse large B-cell lymphoma is present. Your doctor may recommend removing an entire lymph node or just part of one, depending on the location and size of the suspicious area. In some cases, tissue samples may be taken from other parts of the body if imaging tests suggest the disease has spread beyond lymph nodes.^[3]

In the laboratory, specialized doctors examine the tissue sample to look for cancer cells and determine their specific characteristics. These tests can confirm not only that lymphoma is present but also verify that it is still the same type of lymphoma you had initially. Sometimes lymphomas can change their characteristics over time, and knowing exactly what type of disease you have ensures you receive the most appropriate treatment.

The importance of repeating a biopsy cannot be overstated when relapse is suspected. Even if you’ve already had lymphoma diagnosed before, doctors need to confirm that what they’re seeing on scans is actually lymphoma and not another condition. This extra step, while it may seem frustrating, protects you from receiving treatment for a disease you don’t actually have.^[6]

Bone Marrow Examination

Bone marrow aspiration and biopsy are procedures that collect samples from the soft tissue inside your bones where blood cells are made. These procedures typically involve taking samples from the hip bone. During bone marrow aspiration, a needle draws out a sample of the liquid portion of the marrow. During a bone marrow biopsy, a needle collects a small amount of the solid, spongy tissue.^[3]

These samples are sent to a laboratory where technicians examine them under a microscope to see if lymphoma cells have spread to the bone marrow. Finding lymphoma in the bone marrow indicates more extensive disease and can influence decisions about the intensity of treatment needed.

Diagnostics for Clinical Trial Qualification

When doctors evaluate whether a patient might be eligible to participate in a clinical trial for relapsed or refractory diffuse large B-cell lymphoma, they use specific diagnostic criteria to define exactly what “refractory” means. The SCHOLAR-1 study, which has become a widely-used reference point for clinical trials in this disease, established particular definitions based on diagnostic findings.^[2]

According to these criteria, refractory disease is defined as showing stable disease or progressive disease as the best response to first-line or later treatment. Stable disease means the lymphoma neither grew nor shrank during treatment, while progressive disease means it actually got worse. Patients are also considered to have refractory disease if their lymphoma returns within twelve months after undergoing autologous stem cell transplantation, a intensive treatment procedure.^[2]

Clinical trials often require specific imaging tests to confirm that disease is present and measurable before a patient can enroll. PET scans are frequently used because they can detect metabolically active lymphoma cells. However, as mentioned earlier, PET scans can sometimes show false-positive results, which is why confirmation through biopsy is often required before starting treatment in a clinical trial setting.^[6]

For clinical trial enrollment, doctors also typically assess something called the International Prognostic Index, or IPI, which uses various factors to predict how well a patient might respond to treatment. Blood tests measuring LDH levels contribute to this scoring system. The timing of relapse is another critical factor—whether disease returned early (within twelve months) or later affects both prognosis and eligibility for different types of clinical trials.^[7]

Some clinical trials specifically focus on patients whose disease has certain molecular or genetic characteristics. In these cases, additional specialized laboratory tests on biopsy samples may be required to determine if the lymphoma has particular markers or mutations that the trial treatment targets. These more sophisticated diagnostic tests help match patients with therapies most likely to benefit them based on the specific biology of their disease.^[4]

Prognosis and Survival Rate

Prognosis

The prognosis for patients with relapsed or refractory diffuse large B-cell lymphoma depends heavily on several factors that doctors identify through diagnostic testing. The timing of relapse plays a crucial role—patients whose disease returns or proves refractory within twelve months of initial treatment generally face more challenging outcomes than those who relapse later. The International Prognostic Index score at the time of relapse, which incorporates factors like LDH levels and other disease characteristics, also affects the likely course of the disease.^[11]

Historically, outcomes for refractory disease have been quite poor, though recent advances in treatment options have begun to improve the picture for some patients. The effectiveness of salvage chemotherapy and whether a patient is eligible for intensive treatments like stem cell transplantation or CAR T-cell therapy significantly impacts prognosis. Patients who respond well to salvage chemotherapy and can proceed to transplantation have better chances of long-term survival compared to those whose disease doesn’t respond to second-line treatments.^[11]

Various biological factors discovered through diagnostic testing also affect prognosis. The specific molecular characteristics of the lymphoma, identified through specialized laboratory tests on biopsy samples, can indicate whether the disease is likely to respond to certain treatments. Additionally, a patient’s overall health status and ability to tolerate intensive therapy influences outcomes considerably.^[11]

Survival Rate

The SCHOLAR-1 study, which examined 636 patients with refractory diffuse large B-cell lymphoma, provides sobering statistics about survival rates. This landmark research found that the median overall survival was only 6.3 months for patients with refractory disease, meaning half of patients survived less than this time and half survived longer. The two-year overall survival rate was just 20%, indicating that only one in five patients was still alive two years after their disease was classified as refractory.^[2]

The objective response rate to the next line of therapy after disease was deemed refractory was 26%, but only 7% of patients achieved complete remission. These statistics underscore how challenging refractory disease is to treat with conventional approaches, though it’s important to note that these numbers come from data collected before some newer treatments became available.^[2]

For patients whose disease responds to treatment and who are able to proceed to stem cell transplantation, survival rates improve considerably. Among those who respond sufficiently to salvage chemotherapy and undergo autologous stem cell transplant, long-term disease-free survival can be achieved. However, historically, over 80% of patients with relapsed or refractory disease either failed to respond adequately to second-line chemotherapy or were ineligible to receive transplant, leaving only about 20% of patients potentially cured in the relapsed setting through transplant approaches.^[7]

More recently, CAR T-cell therapy has shown promising results that are beginning to change these statistics for some patients. When used in the third-line setting or later, CAR T-cell therapy demonstrated a five-year overall survival of 42.6%, confirming its potential to achieve long-term remissions in patients who previously would have had very limited options.^[7]

#1 Clinical Trials Search in Europe

Diffuse large B-cell lymphoma refractory – Diagnostics

Introduction: Who Should Undergo Diagnostics